| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Alone, lonely, and missed
|
Kahn, James
|
|
|
9 |
6 |
p. 565-566
|
article
|
| 2 |
A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe COVID-19
|
McGonagle, Dennis
|
|
|
9 |
6 |
p. 665-672
|
article
|
| 3 |
Challenges and opportunities to end tuberculosis in the COVID-19 era
|
Wingfield, Tom
|
|
|
9 |
6 |
p. 556-558
|
article
|
| 4 |
Correction to Lancet Respir Med 2021; published online April 9. https://doi. org/10.1016/S2213-2600(21)00160-0
|
|
|
|
9 |
6 |
p. e55
|
article
|
| 5 |
Correction to Lancet Respir Med 2021; published online April 19. https://doi.org/10.1016/S2213-2600(21)00096-5
|
|
|
|
9 |
6 |
p. e55
|
article
|
| 6 |
Correction to Lancet Respir Med 2021; published online April 9. https://doi. org/10.1016/S2213-2600(21)00171-5
|
|
|
|
9 |
6 |
p. e55
|
article
|
| 7 |
Correction to Lancet Respir Med 2021; published online Feb 26. https://doi.org/10.1016/S2213-2600(20)30448-3
|
|
|
|
9 |
6 |
p. e55
|
article
|
| 8 |
COVID-19 pathophysiology: looking beyond acute disease
|
The Lancet Respiratory Medicine,
|
|
|
9 |
6 |
p. 545
|
article
|
| 9 |
COVID-19 survivor experiencing long-term symptoms
|
Kirby, Tony
|
|
|
9 |
6 |
p. 570-572
|
article
|
| 10 |
Desperation in the time of COVID-19
|
Adhikari, Biplov
|
|
|
9 |
6 |
p. 567-569
|
article
|
| 11 |
Development of new antibacterial agents: a sense of urgency needed
|
Burki, Talha Khan
|
|
|
9 |
6 |
p. e54
|
article
|
| 12 |
Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
|
Shostak, Yael
|
|
|
9 |
6 |
p. e52-e53
|
article
|
| 13 |
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
|
Yap, Timothy A
|
|
|
9 |
6 |
p. 613-621
|
article
|
| 14 |
Evidence-based European guidelines for the diagnosis of asthma in children aged 5–16 years
|
Gaillard, Erol A
|
|
|
9 |
6 |
p. 558-560
|
article
|
| 15 |
From female warriors in the rainforest to infectious disease specialists: COVID-19 in the Amazon
|
Safe, Izabella
|
|
|
9 |
6 |
p. 566-567
|
article
|
| 16 |
Has the time come to end use of the blue inhaler?
|
Bush, Andrew
|
|
|
9 |
6 |
p. e51
|
article
|
| 17 |
High COVID-19 death rates in prisons in England and Wales, and the need for early vaccination
|
Braithwaite, Isobel
|
|
|
9 |
6 |
p. 569-570
|
article
|
| 18 |
Immunotherapy in COVID-19: why, who, and when?
|
Sinha, Pratik
|
|
|
9 |
6 |
p. 549-551
|
article
|
| 19 |
Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice
|
Khanna, Dinesh
|
|
|
9 |
6 |
p. 560-562
|
article
|
| 20 |
Interleukin-6: obstacles to targeting a complex cytokine in critical illness
|
McElvaney, Oliver J
|
|
|
9 |
6 |
p. 643-654
|
article
|
| 21 |
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
|
Angriman, Federico
|
|
|
9 |
6 |
p. 655-664
|
article
|
| 22 |
Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study
|
Combs, Michael P
|
|
|
9 |
6 |
p. 601-612
|
article
|
| 23 |
New and old treatments for malignant mesothelioma: not just immunotherapy
|
Nowak, Anna K
|
|
|
9 |
6 |
p. 547-549
|
article
|
| 24 |
Non-invasive respiratory support strategies in COVID-19
|
Gorman, Ellen
|
|
|
9 |
6 |
p. 553-556
|
article
|
| 25 |
REPLACE and the role of riociguat in pulmonary arterial hypertension therapy
|
Frantz, Robert P
|
|
|
9 |
6 |
p. 546-547
|
article
|
| 26 |
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
|
Fennell, Dean A
|
|
|
9 |
6 |
p. 593-600
|
article
|
| 27 |
Saliva as a gold-standard sample for SARS-CoV-2 detection
|
Tan, Steph H
|
|
|
9 |
6 |
p. 562-564
|
article
|
| 28 |
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
|
Hoeper, Marius M
|
|
|
9 |
6 |
p. 573-584
|
article
|
| 29 |
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
|
de Gooijer, Cornedine J
|
|
|
9 |
6 |
p. 585-592
|
article
|
| 30 |
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity
|
Osuchowski, Marcin F
|
|
|
9 |
6 |
p. 622-642
|
article
|
| 31 |
Vascular mechanisms and manifestations of COVID-19
|
Levi, Marcel
|
|
|
9 |
6 |
p. 551-553
|
article
|
Journal description